Under 10 U.S.C. 2304c(e)(1), the GAO has jurisdiction to hear protests of task orders issued under multiple-award contracts where the task order is “valued in excess of $10,000,000.”  Last week, GAO issued a decision that clarifies what determines the “value” of a task order for purposes of this limitation on GAO’s jurisdiction.

In Goldbelt Glacier Health Services, LLC, B-410378, B-410378.2 (Sept. 25, 2014), GAO dismissed for lack of jurisdiction Glacier’s protest of the Army National Guard’s award of a task order for psychological health services to another bidder for a price of $9.6 million.  Glacier had argued that the $10 million jurisdictional threshold was satisfied because, had the agency conducted a proper evaluation, it would have awarded the order to Glacier for its proposed price of $11.4 million.  Glacier contended that the work to be performed under the task order could not be performed for less than $10 million.

GAO refused Glacier’s invitation to consider the “true” or “underlying” value of the work to be performed.  Instead, it adopted a bright-line rule:  where the government has issued a task order, the jurisdictional limit “turn[s] on the value of the disputed order, which is reflected in the terms of the order itself since the order defines the scope and terms of the contractual commitment between the selected contractor and the government.”

Impact for Contractors:  GAO’s holding has implications for contractors bidding on task orders near the $10 million jurisdictional threshold.  In particular, it clarifies that GAO’s jurisdiction to hear a protest over a task order will be determined by the winning bidder’s price alone.  Contractors competing for task orders in that value range should be aware that their protest rights might be impaired, in that a competitor’s bid of slightly less than $10 million will likely render the award immune from protest at the GAO.  It is conceivable that agencies might take this consideration into account in best-value tradeoff evaluations, although it is not at all clear that such consideration would be appropriate (and might itself be subject to challenge).

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Jennifer Plitsch Jennifer Plitsch

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She…

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She has particular expertise in advising clients on intellectual property and data rights issues under the Federal Acquisition Regulations (FAR) and obligations imposed by the Bayh-Dole Act, including march-in and substantial domestic manufacturing. Jen also has significant experience in negotiation and compliance under non-traditional government agreements including Other Transaction Authority agreements (OTAs), Cooperative Research and Development Agreements (CRADAs), Cooperative Agreements, Grants, and Small Business Innovation Research agreements.

For over 20 years, Jen’s practice has focused on advising clients in the pharmaceutical, biologics and medical device industry on all aspects of both commercial and non-commercial agreements with various government agencies including:

  • the Department of Veterans Affairs (VA);
  • the Department of Health and Human Services (HHS), including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), and the Centers for Disease Control (CDC);
  • the Department of Defense (DoD), including the Defense Threat Reduction Agency (DTRA), the Defense Advanced Research Projects Agency (DARPA), and the Joint Program Executive Office for Chemical Biological Defense (JPEO-CBRN); and
  • the U.S. Agency for International Development (USAID).

She regularly advises on the development, production, and supply to the government of vaccines and other medical countermeasures addressing threats such as COVID-19, Ebola, Zika, MERS-CoV, Smallpox, seasonal and pandemic influenza, tropical diseases, botulinum toxin, nerve agents, and radiation events. In addition, for commercial drugs, biologics, and medical devices, Jen advises on Federal Supply Schedule contracts, including the complex pricing requirements imposed on products under the Veterans Health Care Act, as well as on the obligations imposed by participation in the 340B Drug Pricing program.

Jen also has significant experience in domestic sourcing compliance under the Buy American Act (BAA) and the Trade Agreements Act (TAA), including regulatory analysis and comments, certifications, investigations, and disclosures (including under the Acetris decision and Biden Administration Executive Orders). She also advises on prevailing wage requirements, including those imposed through the Davis-Bacon Act and the Service Contract Labor Standards.